MAKENA KELLY: Open Payments
NPI 1093306169 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,712 in 165 payments from 44 companies in 2025. Trend: 2023 $4,777 · 2024 $4,422 · 2025 $3,712
Food & beverage: $3,712
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $375 |
| Novartis Pharmaceuticals Corporation | 22 | $324 |
| Merck Sharp & Dohme LLC | 11 | $302 |
| PFIZER INC. | 11 | $250 |
| E.R. Squibb & Sons, L.L.C. | 12 | $204 |
| ABBVIE INC. | 9 | $187 |
| AstraZeneca Pharmaceuticals LP | 8 | $184 |
| Incyte Corporation | 9 | $175 |
| Lilly USA, LLC | 5 | $128 |
| TerSera Therapeutics LLC | 4 | $118 |
Products named: KEYTRUDA, RYBREVANT, SCEMBLIX, OPDIVO, JAKAFI, VERZENIO, ERLEADA, IBRANCE.
Industry payments across ID — which companies pay providers there.
